Structure Therapeutics (NASDAQ:GPCR) vs. Bioxytran (OTCMKTS:BIXT) Head-To-Head Analysis

Bioxytran (OTCMKTS:BIXT) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Institutional & Insider Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. 70.0% of Bioxytran shares are owned by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Bioxytran has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.64, meaning that its share price is 264% less volatile than the S&P 500.

Valuation and Earnings

This table compares Bioxytran and Structure Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioxytran	N/A	N/A	-$2.37 million	($0.03)	-2.28
Structure Therapeutics	N/A	N/A	-$122.53 million	($1.22)	-49.94

Structure Therapeutics is trading at a lower price-to-earnings ratio than Bioxytran, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Bioxytran and Structure Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioxytran	0	0	0	0	0.00
Structure Therapeutics	2	0	11	1	2.79

Structure Therapeutics has a consensus target price of $95.78, indicating a potential upside of 57.20%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Bioxytran.

Profitability

This table compares Bioxytran and Structure Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bioxytran	N/A	N/A	-1,510.01%
Structure Therapeutics	N/A	-26.08%	-24.65%

About Bioxytran

Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company’s lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was founded in 2008 and is headquartered in Needham, Massachusetts.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.